RedJay Asset Management Inc. Invests $1.27 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

RedJay Asset Management Inc. bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 2,000 shares of the biopharmaceutical company's stock, valued at approximately $1,268,000.

Other large investors have also added to or reduced their stakes in the company. Marietta Wealth Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 30.2% in the first quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after purchasing an additional 2,501 shares during the last quarter. Pamalican Asset Management Ltd bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $4,915,000. Intact Investment Management Inc. acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at about $356,000. Rhenman & Partners Asset Management AB raised its holdings in Regeneron Pharmaceuticals by 11.4% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock valued at $30,956,000 after acquiring an additional 4,457 shares during the period. Finally, GAMMA Investing LLC lifted its position in Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after acquiring an additional 814,713 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $521.00 on Monday. The company has a market cap of $56.25 billion, a P/E ratio of 13.26, a PEG ratio of 1.91 and a beta of 0.31. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The company's 50 day moving average is $554.18 and its 200-day moving average is $631.19. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business's quarterly revenue was down 3.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $9.55 EPS. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.68%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.96%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on REGN shares. UBS Group decreased their target price on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a research report on Thursday, June 5th. Cantor Fitzgerald assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price objective on the stock. Morgan Stanley lowered their price objective on Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating on the stock in a research report on Monday, June 2nd. Citigroup reduced their target price on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a research report on Monday, June 2nd. Finally, JPMorgan Chase & Co. lowered their price target on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research report on Monday, June 9th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $822.58.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.